COVID-19 Treatment of patients with severe or critical COVID-19

The COVID-19 Treatment Guidelines Panel recommends against the use of interferons for the treatment of patients with severe or critical COVID-19, except in a clinical trial (AIII). There are insufficient data to recommend either for or against the use of interferon beta for the treatment of early (i.e., <7 days from symptom onset) mild and moderate COVID-19.
https://www.residentadvisor.net/events/1431179
https://www.residentadvisor.net/events/1431179
https://www.residentadvisor.net/events/1431187
https://www.residentadvisor.net/events/1431192
https://www.residentadvisor.net/events/1431193
https://www.residentadvisor.net/events/1431196
https://www.residentadvisor.net/events/1431197
https://www.residentadvisor.net/events/1431198
https://www.residentadvisor.net/events/1431199
https://www.residentadvisor.net/events/1431200
https://www.residentadvisor.net/events/1431201
https://www.residentadvisor.net/events/1431202
https://www.residentadvisor.net/events/1431203
https://www.residentadvisor.net/events/1431204
https://www.residentadvisor.net/events/1431205
https://www.residentadvisor.net/events/1431206
https://www.residentadvisor.net/events/1431207
https://www.residentadvisor.net/events/1431208
https://www.residentadvisor.net/events/1431209
Rationale
Studies have shown no benefit of interferons in patients with other coronavirus infections (i.e., Middle East respiratory syndrome [MERS], severe acute respiratory syndrome [SARS]) who have severe or critical disease. In addition, interferons have significant toxicities that outweigh the potential for benefit. Interferons may have antiviral activity early in the course of infection. However, there is insufficient data to assess the potential benefit of interferon use during early disease versus the toxicity risks.
Clinical Data for COVID-19